JCO: ORR for first-line treatment of patients with renal transparent cell carcinoma in the advance stage of Paboli pearl monotherapy up to 36.4%

Patients with renal transparent cell carcinoma (ccRCC) in the advance stage of paboliju monotherapy were safe and effective and had a long-lasting response (ORR, 36.4%; CR, 3.6%; PR, 32.7%).
February 2, Journal of Clinical Oncology published an open label, single arm, and clinical Phase II study of the single-drug treatment of ccRCC patients.
study aims to study the efficacy and safety of PD-1 inhibitor Pabliju monodrative therapy in patients with relapsed or advanced or metastatic ccRCC who have not received systemic anti-cancer treatment.
study included 110 patients, with ORR of 36.4% (95% CI, 27.4 to 46.1), of which 4 (3.6%) were fully remission and 36 (32.7%) were partially relieved.
disease control rate was 58.2% (95% CI s 48.4-67.5).
the majority of patients (68.2 per cent, 75/110) had a reduction in lesions, of which 30.9 per cent (34/110) had a 60 per cent reduction in lesions.
18.9 months, and 64.1% of respondents had a mitigation duration of more than 12 months.
the medium non-progressed lifetime was 7.1 months (95% CI -5.6-11.0), with a PFS rate of 37.6% in December and 22.3% in December.
did not reach the mid-level OS, with OS rates of 88.2% in December and 70.8% in 24.
42 patients had a good IMDC risk and 68 patients had a moderate or adverse IMDC risk.
results of the IMDC risk category showed that the ORR of the good IMDC risk group was 31.0% (95% CI, 17.6 to 47.1), of which 1 case (2.4%) was fully mitigated and 12 cases (28.6%) were partially alleviated.
ORR in the medium or bad IMDC risk group was 39.7% (95% CI, 28.0 to 52.3), of which 3 (4.4%) were fully mitigated and 24 (35.3%) were partially mitigated.
CPS in 52 patients ≥ 1,58 patients had CPS <1.
results expressed by PD-L1 showed that the ORR in the CPS≥1 group was 44.2% and the ORR in the CPS<1 group was 29.3% 30.0% of patients with treatment-related adverse events, the most common of which were colitis (5.5%) and diarrhea (3.6%).
three patients died from adverse events and one from treatment-related pneumonia.
Despite the inherent limitations of single-arm design, the results of this study show that Pabliju monotherapy has convincing anti-tumor activity, safe and long-lasting, for patients with advanced ccRCC (including all IMDC risk groups) and all patients with IMDC risk.
has the potential to become a treatment for patients with advanced ccRCC who are less resistant to other drugs.
these results support the further exploration of Pabliju monotherapy, complementary therapy, and this-based combined therapy in patients with late-stage or metastasis ccRCC.
: David F. McDermott, Jae-Lyun Lee, Georg A. Bjarnason, et al. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. February 02, 2021. DOI: 10.1200/JCO.20.02363 Journal of Clinical Oncology.MedSci Original Source: MedSci Original Copyright Notice: All Noted on this website Source: Met Medical Or "Source: MedSci Original" text, images and audio-visual materials, copyrights are owned by Metz Medicine, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here